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Abstract
Background: The current study sought to investigate the impact of tumor size and
total number of LN examined (TNLE) on the incidence of lymph node metastasis
(LNM) among patients with duodenal neuroendocrine tumor (dNET).
Methods: Patients who underwent curative resection for dNETs between 1997‐2016
were identified from 8 high‐volume US centers. Risk factors associated with overall
survival and LNM were identified and the optimal cut‐off of TNLE relative to LNM
was determined.
Results: Among 162 patients who underwent resection of dNETs, median patient age
was 59 (interquartile range [IQR], 51‐68) years and median tumor size was 1.2 cm
(IQR, 0.7‐2.0 cm); a total of 101 (62.3%) patients underwent a concomitant LND at
the time of surgery. Utilization of lymphadenectomy (LND) increased relative to
tumor size (≤1 cm:52.2% vs 1‐2 cm:61.4% vs >2 cm:93.8%; P < .05). Similarly, the
incidence of LNM increased with dNET size (≤1 cm: 40.0% vs 1‐2 cm:65.7% vs
>2 cm:80.0%; P < .05). TNLE ≥ 8 had the highest discriminatory power relative to the
incidence of LNM (area under the curve = 0.676). On multivariable analysis, while
LNM was not associated with prognosis (hazard ratio [HR] = 0.9; 95% confidence
intervals [95%CI], 0.4‐2.3), G2/G3 tumor grade was (HR = 1.5; 95%CI, 1.0‐2.1).
Conclusions:While the incidence of LNM directly correlated with tumor size, patients
with dNETs ≤ 1 cm had a 40% incidence of LNM. Regional lymphadenectomy of a
least 8 LN was needed to stage patients accurately.
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1 | INTRODUCTION
Duodenal neuroendocrine tumors (dNETs) represent up to 3% of all
primary duodenal malignancies and 2%‐3% of all gastrointestinal
neuroendocrine tumors (NETs).1-3 The incidence of dNETs has
increased from 0.027/100 000 in 1983 to 1.1/100 000 in 2010, perhaps
reflecting the increased use of gastrointestinal endoscopy.4,5 According
to the latest population study in the United States, dNETs present most
often in the 6th decade of life and males are slightly more predominant
than females.6 In turn, resection of dNETs generally represents the most
common modality associated with the best chance at cure.
Although dNETs are usually small on presentation (ie, 75% of
cases ≤20mm), regional lymph node (LN) metastasis has been
reported in up to 40%‐80% of cases.7-10 Current treatment guide-
lines recommend treatment strategies for dNETs that are similar to
gastric NETs for nonfunctional tumors and similar to pancreatic NETs
for functional dNETs.11 For example, the European Neuroendocrine
Tumor Society (ENETS) consensus guidelines generally recommend
surgical treatment for large (>20mm) and/or metastatic dNETs, as
well as periampullary dNETs.11 More often dNET cases are now
diagnosed, however, incidentally when the tumors are small in size
(<10mm), well‐differentiated, limited to the mucosa and submucosa,
and nonfunctioning. In turn, endoscopic local excision may be
increasingly considered for these early‐stage tumors rather than
surgical resection.12 The impact of not staging the nodal basin in the
setting of endoscopic excision remains poorly defined. Unfortunately,
data on the clinical characteristics, tumor biology, treatment, and
prognosis of patients with dNETs have been limited largely to small,
single‐center case series.12-14 Therefore, the objective of the current
study was to define the outcomes of patients who underwent
curative‐intent resection for periampullary and nonampullary dNETs
using a large, multi‐institutional database. Specifically, the aim was to
characterize potential risk factors associated with the presence of
lymph node metastasis (LNM), as well as identify the minimal number
of LN needed to stage patients optimally.
2 | METHODS
2.1 | Study cohort and data collection
Patients who underwent surgical resection for dNETs between 1997
and 2016 were identified from the US Neuroendocrine Tumor Study
Group (US‐NETSG).15 All patients were diagnosed with dNETs, which
were confirmed by histological examination. Patients who presented
with distant metastasis or underwent cytoreductive/palliative (R2)
resection were excluded. The study was approved by the Institutional
Review Boards at each participating institution.
A standardized datasheet was utilized to collect the demographic,
clinical, and pathologic data at each institution. Largest tumor size,
primary tumor location, the total number of LNs examined (TNLE), the
number of LNM, perineural invasion, lymphovascular invasion, and
surgical margin status were determined based on the final pathological
report. The tumors were staged according to the eighth TMN stage
scoring system16 and classified as grade G1 (Ki‐67 ≤2%), G2 (Ki‐67 3%‐
20%), and G3 (Ki‐67 >20%) according to theWHO 2010 classification.17
Overall survival (OS) was calculated from the date of surgery to the
date of death or date of last follow‐up. Tumor recurrence was
determined by suspicious imaging finding or biopsy‐proven tumor.
2.2 | Statistical analysis
Categorical variables were reported as totals and percentages and
compared by χ2 test or Fisher exact test as appropriate. Continuous
variables were expressed as median with interquartile ranges (IQRs) and
compared using the Mann‐Whitney U test. Kaplan‐Meier survival curves
were plotted and compared using the logrank test. The receiver‐
operating characteristic curve analysis was used to investigate the
discriminatory ability of TNLE relative to the number of LNM. Risk
factors associated with OS or LNM were identified by using Cox‐
proportional hazard regression models or Logistic regression models,
respectively. Results were reported as hazard ratios (HRs) or odds ratio
(OR) and 95% confidence intervals (95%CI). A P‐value <0.05 (two‐tailed)
was considered statistically significant for all analyses. Statistical analyses
were performed using SPSS 22.0 (IBM, Chicago, IL).
3 | RESULTS
3.1 | Baseline characteristics
Among 162 patients with dNETs, median patient age was 59 (IQR, 51‐68)
years and 53.7% (n=87) of patients were male (Table 1). Roughly one‐in‐
five (n=34/162, 21.0%) patients had a functional tumor; gastrinoma
(n=31/34, 91.2%) was the predominant tumor type. The overwhelming
majority of patients had no designated syndrome (n=146, 90.1%),
whereas a small subset of individuals had multiple endocrine neoplasia
type 1 (n=8, 4.9%) or neurofibromatosis syndrome (n=4, 2.5%).
Abdominal pain (47.5%) was the most common symptom. The majority
(n=127, 78.4%) of patients underwent an open surgical procedure.
Surgical procedures included transduodenal resection (n=25, 15.4%),
partial duodenectomy (n=20, 12.3%), segmental duodenectomy (n=33,
20.4%), and pancreaticoduodenectomy (PD) (n=52, 32.1%); 30 (18.5%)
patients underwent an endoscopic resection. Based on final pathological
assessment, median tumor size was 1.2 cm (IQR, 0.7‐2.0 cm). A total of
101 (62.3%) patients underwent a concomitant lymphadenectomy (LND)
at the time of surgery (transduodenal resection, n=11; partial
duodenectomy, n=14; segmental duodenectomy, n=26; PD, n=50);
median TNLE was 10 (IQR, 3‐16). Among patients who underwent LND
(n=101), at least one LNM was identified in 61 (60.4%) patients. The
overall incidence of procedure‐related complications was 48.1% (n=78)
with 22.8% (n=37) of patients experiencing a severe Clavien‐Dindo III‐V
complication.
3.2 | Periampullary versus nonampullary dNETs
In assessing the cohort, 127 (78.4%) patients had a dNET located in
the duodenum away from ampulla of Vater, whereas 35 (21.6%)
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TABLE 1 Clinicopathologic characteristics and surgical procedures
Overall (n = 162) Periampullary dNETs (n = 35) Nonampullary dNETs (n = 127) P‐value
Age (y) 59 (51‐68) 56 (50‐70) 59 (52‐68) 0.559
Sex 0.340
Male 87 (53.7%) 16 (45.7%) 16 (45.7%)
Female 75 (46.3%) 19 (54.3%) 19 (54.3%)
Nonfunctional tumor 128 (79.0%) 30 (85.7%) 98 (77.2%) 0.352
Functional tumor 34 (21.0%) 5 (14.3%) 29 (22.8%) 0.326
Gastrinoma 31 (19.1%) 4 (11.4%) 27 (21.3%)
Somatostatinoma 2 (1.2%) 1 (2.9%) 1 (0.8%)
Glucagonoma 1 (0.6%) ‐ 1 (0.8%)
Genetic syndrome 0.059
None 146 (90.1%) 30 (85.7%) 116 (91.3%)
MEN 1 8 (4.9%) 1 (2.9%) 7 (5.5%)
Neurofibromatosis 4 (2.5%) 3 (8.6%) 1 (0.8%)
NA 4 (2.5%) 1 (2.9%) 6 (2.4%)
Symptomatic 121 (74.7%) 28 (80.0%) 93 (73.2%) 0.515
Abdominal pain 77 (47.5%) 24 (68.6%) 53 (41.7%) 0.007
Clinical jaundice 10 (6.2%) 8 (22.9%) 2 (1.6%) <0.001
Gastrointestinal bleeding 21 (13.0%) 2 (5.7%) 19 (15.0%) 0.254
Diarrhea 33 (20.4%) 7 (20.0%) 26 (20.5%) 1.000
Nausea/vomiting 37 (22.8%) 11 (31.4%) 26 (20.5%) 0.182
Preoperative FNA 47 (29.0%) 14 (40.0%) 33 (26.0%) 0.141
Primary location
D1 76 (46.9%) ‐ 76 (59.8%)
D2 26 (16.0%) ‐ 26 (20.5%)
D1+D2 7 (4.3%) ‐ 7 (5.5%)
D3/D4 4 (2.5%) ‐ 4 (3.1%)
Surgery technique 0.267
Endoscopic 30 (18.5%) 4 (11.4%) 26 (20.5%)
Open 127 (78.4%) 30 (85.7%) 97 (76.4%)
Laparoscopic 4 (2.5%) ‐ 4 (3.1%)
Type of resection <0.001
Endoscopic resection 30 (18.5%) 4 (11.4%) 26 (20.5%)
Transduodenal resection 25 (15.4%) 9 (25.7%) 16 (12.6%)
Partial duodenectomy 20 (12.3%) ‐ 20 (15.7%)
Segmental duodenectomy 33 (20.4%) ‐ 33 (26.0%)
Pancreaticoduodenectomy 52 (32.1%) 21 (60.0%) 31 (24.4%)
Operation time (min) 200 (138‐306) 250 (154‐375) 196 (133‐302) 0.082
Blood loss (mL) 125 (25‐300) 200 (50‐500) 100 (20‐300) 0.074
Surgical margin 1.000
R0 131 (80.9%) 28 (80.0%) 103 (81.1%)
R1 23 (14.2%) 5 (14.3%) 18 (14.2%)
Largest tumor size (cm) 1.2 (0.7‐2.0) 1.8 (1.2‐2.5) 1.1 (0.7‐1.7) 0.019
Tumor number 0.044
Single 141 (87.0%) 34 (97.1%) 107 (84.3%)
Multiple 21 (13.0%) 1 (2.9%) 20 (15.7%)
Lymphadenectomy 101 (62.3%) 24 (68.6%) 77 (60.6%) 0.424
No. of lymph node examined 10 (3‐16) 15 (11‐21) 7 (2‐15) 0.005
Lymph nodes status 0.241
Negative 40 (39.6%) 7 (29.2%) 33 (42.9%)
Positive 61 (60.4%) 17 (70.8%) 44 (57.1%)
No. of positive lymph nodes 2 (1‐4) 4 (2‐6) 2 (1‐3) 0.285
(Continues)
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TABLE 1 (Continued)
Overall (n = 162) Periampullary dNETs (n = 35) Nonampullary dNETs (n = 127) P‐value
WHO classification 0.104
G1 106 (65.4%) 22 (62.9%) 84 (66.1%)
G2 51 (31.5%) 10 (28.6%) 22 (32.3%)
G3 5 (3.1%) 3 (8.6%) 2 (1.6%)
AJCC T stage 0.018
T1 56 (34.6%) 5 (14.3%) 51 (40.2%)
T2 61 (37.7%) 17 (48.6%) 44 (34.6%)
T3 21 (13.0%) 8 (22.9%) 13 (10.2%)
T4 6 (3.7%) 2 (5.8%) 4 (3.1%)
Lymph‐vascular invasion 31 (19.1%) 11 (31.4%) 20 (15.7%) 0.184
Perineural invasion 12 (7.4%) 3 (8.6%) 9 (7.1%) 1.000
Postoperative morbidity 78 (48.1%) 18 (51.4%) 60 (47.2%) 0.705
Severe complication (III‐V) 37 (22.8%) 10 (28.6%) 27 (21.3%) 0.432
Length of stay (d) 7 (5‐11) 15 (7‐21) 7 (4‐11) 0.029
Abbreviations: AJCC, American Joint Committee on Cancer; dNETs, duodenal neuroendocrine tumors; MEN 1, multiple endocrine neoplasia type 1.
F IGURE 1 A, overall survival of the
whole cohort (n = 162); B, overall survival
of patients with periampullary (n = 35) or
nonampullary (n = 127) duodenal
neuroendocrine tumors
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patients had a periampullary dNET. Clinicopathologic characteris-
tics and surgical procedures associated with nonperi‐ampullary and
periampullary pNET tumors were largely comparable (Table 1).
Perhaps not surprisingly, patients with periampullary dNETs were
more likely to present with clinical jaundice (22.9% vs 1.6%;
P < .001) and abdominal pain (68.6% vs 41.7%; P = .007) versus
patients with nonampullary dNETs. In addition, more patients who
had a periampullary dNET underwent a PD (n = 21, 60.0%)
compared with only 24.4% (n = 31) of patients with a nonampullary
dNET (P < .001). In turn, patients with a periampullary dNET had a
higher TNLE compared with nonperi‐ampullary dNET (median 15 vs
7, respectively; P = .005)(Table 1). In addition, patients with
periampullary dNETs were more likely to have a single tumor that
was larger in size versus patients who had nonampullary tumors
(both P < .05). In contrast, receipt of LND, as well as incidence and
number of LNM, were not different among patients with ampullary
versus nonampullary dNETs (Table 1).
3.3 | Long‐term survival
With a median follow‐up of 27.2 (IQR, 8.9‐57.0) months, 1‐, 3‐, and 5‐
year OS was 94.2%, 86.9%, and 84.7%, respectively (Figure 1A). Of
note, OS was similar among patients with periampullary versus
nonampullary dNETs (5‐year OS, 70.8% vs 87.3%; P = .944) (Figure
1B). In the subset of patients who underwent PD, OS was also
comparable among patients with periampullary (n = 21) and non-
ampullary (n = 31) dNETs (5‐year OS, 81.0% vs 82.0%; P = 1.000). On
multivariable analysis, only G2/G3 WHO classification was asso-
ciated with a higher risk of worse OS (Reference G1, HR, 1.5; 95%CI,
1.0‐2.1; P = .032). In contrast, tumor location, size, and number,
American Joint Committee on Cancer (AJCC) T stages, nodal status,
as well as treatment procedures were not associated with long‐term
survival of dNETs patients (Table 2).
Among the 18 (11.1%) patients who developed tumor recur-
rence during follow‐up, 9 (50%) developed hepatic recurrence
only, whereas 8 (44.4%) patients developed loco‐regional resec-
tion site and/or LN recurrence; one (5.6%) patient had both loco‐
regional and distant metastasis. Tumor recurrence was no
different among patients with periampullary versus nonampullary
dNETs or among patients undergoing different surgical procedures
(both P > 0.05).
3.4 | Tumor size and nodal metastasis
As tumor size is a key indicator in defining the T category for dNETs in
the AJCC staging manual,16 the impact of tumor size on the proportion of
LND, as well as the incidence of nodal metastasis, was further analyzed.
Of note, LND were performed among almost all (93.8%) patients with
dNET >2 cm compared with 61.4% of patients with tumors of 1 to 2 cm
and 52.2% of patients with tumors ≤1 cm (both P<0.01) (Figure 2A).
Patients with larger tumors were also more likely to have a higher TNLE
(median TNLE>2 cm 14 vs 1‐2 cm 7 vs ≤1 cm 5; P< 0.001) (Figure 2b).
In addition, the incidence of LNM incrementally increased among patients
with tumors≤1 cm, 1 to 2 cm and>2 cm (LNM, 40.0% vs. 65.7% vs.
80.0%, P=0.003) (Figure 2C).
The likelihood to identify LNM was associated with TNLE.
Specifically, TNLE ≥ 8 was associated with a higher incidence of
identifying LNM (TNLE < 8: 20/45, 44.4% vs. TNLE ≥ 8: 41/56,
73.2%; P = .004), as well as a higher number of LNM identified
(median number of LNM, TNLE ≥ 8: 2 [IQR, 1‐5], vs TNLE < 8: 1
[IQR, 1‐2], P < 0.001). In addition, TNLE ≥ 8 had the highest
discriminatory power relative to the incidence of LNM (area
under the curve [AUC] 0.676, sensitivity 67.2%, specificity =
65.0%) (Figure 2D). On multivariable analysis, tumor size (1‐2 cm
vs ≤1 cm (OR, 2.8; 95%CI, 1.0‐8.0; P = .048), >2 cm vs ≤1 cm (OR,
4.6; 95%CI, 1.4‐15.0; P = 0.012), as well as TNLE ≥ 8 vs <8 (OR, 3.6;
95%CI, 1.4‐9.2; P = .007) were associated with the likelihood of
identifying LNM (Table 3).
TABLE 2 Factors associated with overall survival after curative
resection for duodenal neuroendocrine tumors (dNETs)
Univariate analysis Multivariable analysis
HR (95%CI) P value HR (95%CI) P value
Sex (male vs female) 1.3 (0.5‐3.4) 0.535
Functional status 0.4 (0.1‐1.7) 0.202
Symptomatic 0.5 (0.2‐1.1) 0.083
Genetic syndrome 0.4 (0.1‐20.0) 0.309
AJCC T categories
T1 Ref. Ref.
T2 0.8 (0.3‐2.9) 0.835 0.4 (0.1‐1.7) 0.425
T3‐T4 1.9 (1.1‐6.6) 0.024 0.9 (0.2‐4.1) 0.924
Multiple lesions 0.7 (0.2‐3.0) 0.623
Tumor size (cm)
≤1 Ref.
1‐2 0.9 (0.3‐2.5) 0.831
>2 0.9 (0.3‐2.8) 0.913
Tumor location 0.944
Duodenum Ref.










Nodal metastasis 0.5 (0.2‐1.7) 0.260
WHO classification
G1 Ref. Ref.




Perineural invasion 2.6 (0.4‐15.6) 0.296
Abbreviation: 95%CI, 95% confidence intervals; AJCC, American Joint
Committee on Cancer; HR, hazard ratio.
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4 | DISCUSSION
The AJCC TNM staging system for NET incorporates tumor size,
nodal status, and distant metastasis to stratify outcomes of patients
with dNETs. The impact of tumor size and nodal status on prognosis
has, however, not been fully investigated, partially due to the rarity
of this disease. The current study was important as we utilized a large
multi‐institutional database to demonstrate that long‐term survival
of patients with dNETs was comparable among patients with peri‐ or
nonampullary dNETs. Rather than location or size, tumor grade G2/
G3 was the main risk factor associated with worse prognosis. Among
patients who underwent LND, three out of five patients had at least
one LNM. Perhaps not surprisingly, LND was utilized incrementally
more often among patients who had larger dNETs (≤1 cm, 52.2% vs
1‐2 cm, 61.4% vs >2 cm, 93.8%) and the incidence of LNM also
increased (≤1 cm, 40.0% vs 1‐2 cm, 65.7% vs >2 cm, 80.0%). We
noted that the TNLE with the best discriminatory power to ensure
adequate staging of the nodal basin was a TNLE ≥ 8 (AUC, 0.676). In
fact, on multivariable analysis, in addition to tumor size, TNLE ≥ 8 vs
<8 was independently associated with the likelihood of identifying
LNM. Collectively, data from the current study serves to highlight
that patients with dNET generally have a favorable prognosis,
however, the incidence of LNM may be high. Tumor size was
associated with LNM, especially among those patients with a dNET
F IGURE 2 The proportion of lymphadenectomy (LND) (A) and number of LND (B) among patients with different tumor sizes. C, the
incidence of lymph node metastasis (LNM) among patients with different tumor sizes. D, Receiver operative characteristics (ROC) analysis
illustrating that total number of lymph nodes examined (TNLE) ≥8 had the highest discriminatory power relative to LNM
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>1 cm, and the ability to identify LNM depended on the adequacy of
the LND with TNLE ≥ 8 being the optimal TNLE to stage patients with
dNETs.
Duodenal NETs have been anatomically classified most often as
periampullary versus nonampullary. Perhaps not surprisingly, periam-
pullary tumor location was associated with higher likelihood of
abdominal pain (80% vs 73%) and clinical jaundice (22.9% vs 1.6%)
versus nonampullary dNETs due to obstruction of bile and pancreatic
ducts. Consistent with a previous population‐based study,18 the
current study also noted that periampullary dNETs were larger at
the time of presentation compared with nonampullary dNETs. Patients
with periampullary dNETs were also more likely to undergo PD
and had a higher number of LNs examined than patients with
nonampullary dNETs. The incidence of LNM was, however, no
different among patients with periampullary versus nonampullary
dNETs. Consistent with previous data, we also noted that tumor grade
was associated with long‐term survival among patients with both
periampullary and nonampullary dNETs after curative resection.8 In
contrast, Randle et al18 failed to find an association of higher tumor
grade and worse survival among patients with dNETs—especially as
related to patients who had periampullary versus nonampullary
dNETs. The reason for these disparate results are likely multifactorial
yet may be due to patients with periampullary dNET in the current
study being more likely to undergo a more extensive resection, such as
PD, compared with patients included in the study by Randle et al18
who more often underwent a local excision.
Prognosis following curative‐intent resection of dNET was
generally very good with a 5‐year survival of 84.7%, which was
comparable with previous data reported in the literature (66%‐
93.8%).8,19,20 Interesting, the impact of LNM on long‐term outcome
has been controversial. While some studies have suggested that LNM
was associated with a worse prognosis,7,16 data from the current
study, as well as several other previous reports, have not demon-
strated an association of LNM with long‐term prognosis.8,9,21 Given
the low accuracy of preoperative imaging to detect LNM among
dNETs patients, most surgeons advocate for routine LND at the time
of surgical resection of dNETs.12,22 To this point, LNM was present in
over one‐half of all patients with dNETs (60.4%). Perhaps of more
interest, the data clearly demonstrated a strong correlation with
dNET size and the likelihood of LNM, as patients with tumor >2 cm
(80.0%) or 1 to 2 cm (65.7%) in size had a much higher incidence of
LNM than patients with tumors ≤1 cm (40.0%) (P = .003). Margonis
et al10 had similarly reported a higher incidence of LNM among NET
tumors sized >1.5 cm,10 while Burke et al noted a difference in the
incidence of LNM using tumor size using >2 cm as the cut‐off.23
While 1 cm is currently used as the cut‐off size to differentiate T1
from T2 in the AJCC staging manual,11,16 there was still a relatively
high incidence of LNM even among patients with small tumors
(≤1 cm, 40.0%). Whereas surgical resection and lymphadenectomy
has traditionally been recommended for only tumors >1 cm, data in
the current study suggest that patients with dNETs ≤1 cm should also
be considered for LND rather than local excision alone.
The minimal number of LNs needed to examine to achieve accurate
staging of the nodal basin for patients with dNETs has not been defined
in the latest NCCN guidelines.11,16 The topic of TNLE has been an area
of interest for several other hepatopancreatic diseases. In fact, TNLE
among patients with pancreatic and small bowel NETs relative to
recurrence‐free survival and overall survival has been examined by our
group and others.15,24 Using a large multi‐institutional database with
external validation based on the surveillance, epidemiology, and end
results (SEER) registry, we demonstrated that TNLE≥ 8 had the highest
discriminatory power relative to recurrence‐free and overall survival
among patients with pNET who hadone to three LNM, and patients who
had ≥4 LNM in both a multi‐institutional data set and the SEER
database.15 In the current study, we similarly noted that TNLE ≥8 had
the strongest discriminatory power to ensure identification of possible
LNM and optimally stage the nodal basin for patients with dNETs.
Specifically, TNLE ≥8 versus TNLE < 8 was associated with a higher
chance of identifying LNM (73.2% vs 44.4%), as well as a higher number
of LNM identified. Taken together, LND as part of an operative
procedure for patients with dNET should include examination of ≥8 LN
to ensure adequate staging.
Several limitations should be considered when interpreting data
in the current study. While a multi‐institutional study increased the
sample size of the analytic cohort, patient selection, surgical
technique, as well as utilization of LND and pathologic examination
of LN, may have varied at different centers. All participatory centers
were, however, major hepatopancreatic institutions that followed
standard state‐of‐the‐art care guidelines regarding the management
of patients with NET. The current study also did not note a difference
of long‐term survival among patients with versus without LNM. The
TABLE 3 Factors associated with lymph node metastasis (LNM) of
duodenal neuroendocrine tumors (dNETs)
Univariate analysis Multivariable analysis
OR (95%CI) P value OR (95%CI) P value
Sex (female vs male) 2.5 (1.1‐5.6) 0.030 2.6 (1.0‐6.4) 0.046
Functional status
Symptomatic 1.1 (0.4‐3.1) 0.805
Genetic syndrome 2.1 (0.5‐8.2) 0.297
Multiple lesions 1.3 (0.4‐4.2) 0.626
Tumor size (cm)
≤1 Ref. Ref.
1 to 2 2.9 (1.1‐7.6) 0.033 2.8 (1.0‐8.0) 0.048
>2 6.0 (2.0‐18.4) 0.002 4.6 (1.4‐15.0) 0.012
Tumor location 0.819
Duodenum Ref.





≥8 3.4 (1.5‐7.9) 3.6 (1.4‐9.2)
WHO classification
G1 Ref.
G2/G3 1.8 (0.6‐5.7) 0.328
Abbreviations: 95%CI, 95% confidence intervals; OR, odds ratio.
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reason for this may have been due to a lack of statistic power (Type II
error); however, other authors have noted a similar finding and
attributed the lack of prognostic impact to the indolent nature of
dNET and the very good overall prognosis.8,9,21 The current study
also only included patient who underwent curative‐intent resection
and therefore patients receiving nonsurgical treatments were not
available for comparison.
In conclusion, patients with a dNET had an overwhelmingly
favorable prognosis after curative‐intent resection, despite the
relatively high incidence of associated LNM. While the incidence of
LNM directly correlated with tumor size, even patients with dNET
≤1 cm had a 40% incidence of LNM. Regional lymphadenectomy of at
least eight LN was recommended to stage patients accurately.
Interestingly, the presence of LNM was not, however, associated with
long‐term survival; rather, tumor grade was the factor that impacted
prognosis. Collectively, data from the current study should help to
inform the care of patients with dNETs.
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